Urgent Need for Improved Infection Control in Hospitals
Overview of Fungal Infections
The necessity for enhanced infection control measures in hospitals is becoming increasingly critical. A recent study has explored the potential of certain herbicides to help mitigate fungal infections, which result in nearly 2 million fatalities globally each year. Approximately 10% of patients in intensive care units (ICUs) acquire a fungal infection during their hospital stay, leading to a twofold increase in mortality rates among infected individuals compared to those without infections. Moreover, there is a growing prevalence of fungal strains that exhibit resistance to existing antifungal medications, highlighting the urgent demand for new therapeutic options.
Potential of Herbicides in Fungal Infection Control
Fungi share numerous genetic and metabolic characteristics with plants. Researchers hypothesize that specific commercial herbicides, designed to eliminate plants, may also be effective against fungi while remaining safe for humans and animals. A collaborative team of scientists from Australia and China has been investigating a series of herbicides that function by inhibiting a unique enzyme essential for the survival of both plants and fungi. This enzyme is absent in humans and other animals, suggesting that these herbicides could target fungi without adversely affecting patients. The findings were recently published in the Proceedings of the National Academy of Sciences.
Effectiveness of Specific Herbicides
The study began by evaluating the efficacy of various herbicides in combating fungal growth. Among these, the herbicide chlorimuron ethyl demonstrated significant effectiveness in inhibiting multiple fungi types in laboratory Petri dish experiments. When combined with the widely used antifungal drug itraconazole, the results were even more promising. To assess safety, researchers conducted tests by injecting the herbicide into mice, observing no adverse effects, even at elevated concentrations.
Testing on Candida albicans
To further investigate its therapeutic potential, the researchers examined whether the herbicide could eliminate a Candida albicans infection in mice. Candida is a prevalent cause of fungal infections in hospital ICUs and is responsible for yeast infections as well as thrush. Without treatment, a Candida albicans infection can be fatal for infected mice. However, administration of the herbicide resulted in approximately half of the infected mice recovering and surviving, while also reducing the quantity of live fungus found in the organs of most subjects.
Future Prospects and Challenges
Despite these encouraging findings, there remains a long journey ahead before this herbicide can be considered for human use. Further animal testing is necessary to evaluate its efficacy against a broader range of fungal infections. Subsequent evaluations will also be required to ensure safety and determine compatibility with existing antifungal medications. Nevertheless, the researchers express optimism regarding the potential of this class of drugs to treat fungal infections in humans and enhance infection control measures in healthcare settings.
References
– Garcia, M. D., Chua, S. M. H., Low, Y.-S., Lee, Y.-T., Agnew-Francis, K., Wang, J.-G., Nouwens, A., Lonhienne, T., Williams, C. M., Fraser, J. A. & Guddat, L. W. Commercial AHAS-inhibiting herbicides are promising drug leads for the treatment of human fungal pathogenic infections. Proceedings of the National Academy of Sciences 115, E9649-E9658 (2018).
– Vincent, J., Rello, J., Marshall, J. & et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 302, 2323-2329 (2009).